"versionIdentifier","rationale","instanceType","uuid:ID","id"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","30bd6fd2-e0f2-4112-9fa6-78433b6d7c28","StudyVersion_1"
